Article Information
History
- August 18, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Renée Bazin1,*,
- Samuel Rochette2,
- Josée Perreault1,
- Marie-Josée Fournier1,
- Yves Grégoire1,
- Amélie Boivin2,
- Antoine Lewin2,3,
- Marc Germain1 and
- Christian Renaud2,4
- 1Affaires Médicales et Innovation, Héma-Québec, Québec, QC, Canada, GIV 4C3
- 2Affaires Médicales et Innovation, Héma-Québec, Montréal, QC, Canada, H4R 2W7
- 3Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada, J1K 2R1
- 4Département de microbiologie, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, H3T 1C5
- ↵*CORRESPONDANCE AND REQUEST FOR REPRINTS: Renée Bazin, PhD, Scientific Director, Medical Affairs and Innovation, Héma-Québec, 1070 Ave des Sciences-de-la-Vie, Québec, QC Canada G1V 5C3, Phone: +1 418 780 4362 ext 3234; Fax: +1 418 780 2091, Email: renee.bazin{at}hema-quebec.qc.ca
Posted August 18, 2022.
Development and use of a method based on the anti-N reactivity of longitudinal samples to better estimate SARS-CoV-2 seroprevalence in a vaccinated population
